Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch

Vaccine

Volumn 31, Issue 34, 2013, Pages 3396-3402

  Moon, Sungsil ^a   Wang, Yuhuan ^a   Edens, Chris ^b   Gentsch, Jon R ^a   Prausnitz, Mark R ^b,c   Jiang, Baoming ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Emory University   (United States)

^c Georgia Institute of Technology   (United States)

Author keywords

IRV; Microneedle; Rotavirus; Skin immunization

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INACTIVATED VIRUS VACCINE; ROTAVIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MICRONEEDLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TH2 CELL; TRANSDERMAL PATCH; VIRUS NEUTRALIZATION;

IRV; MICRONEEDLE; ROTAVIRUS; SKIN IMMUNIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGENS, VIRAL; DENDRITIC CELLS; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; NEEDLES; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SKIN; SPLEEN; TRANSDERMAL PATCH; VACCINATION; VACCINES, INACTIVATED;

EID: 84880509930     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.027     Document Type: Article

References (35)

1. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D., et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:136-141.
2. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
3. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.[see comment]. N Engl J Med 2006, 354:23-33.
4. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
5. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623.
6. Narang A., Bose A., Pandit A.N., Dutta P., Kang G., Bhattacharya S.K., et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Hum Vaccin 2009, 5:414-419.
7. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:606-614.
8. Patel M., Pedreira C., De Oliveira L.H., Tate J., Orozco M., Mercado J., et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009, 301:2243-2251.
9. Patel M.M., Lopez-Collada V.R., Bulhoes M.M., De Oliveira L.H., Bautista Marquez A., Flannery B., et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011, 364:2283-2292.
10. Buttery J.P., Danchin M.H., Lee K.J., Carlin J.B., Mcintyre P.B., Elliott E.J., et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the national immunization program in Australia. Vaccine 2011, 29:3061-3066.
11. Moon S.S., Wang Y., Shane A.L., Nguyen T., Ray P., Dennehy P., et al. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J 2010, 29:919-923.
12. Jiang B., Gentsch J.R., Glass R.I. Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine 2008, 26:6754-6758.
13. Esona M.D., Foytich K., Wang Y., Shin G., Wei G., Gentsch J.R., et al. Molecular characterization of human rotavirus vaccine strain CDC-9 during sequential passages in Vero cells. Hum Vaccin 2010, 6:247-253.
14. Jiang B., Wang Y., Saluzzo J.F., Bargeron K., Frachette M.J., Glass R.I., et al. Immunogenicity of a thermally inactivated rotavirus vaccine in mice. Hum Vaccin 2008, 4:143-147.
15. Wang Y., Azevedo M., Saif L.J., Gentsch J.R., Glass R.I., Jiang B. Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. Vaccine 2010, 28:5432-5436.
16. Lambert P.H., Laurent P.E. Intradermal vaccine delivery: will new delivery systems transform vaccine administration?. Vaccine 2008, 26:3197-3208.
17. Weniger B.G., Papania M.J. Alternative vaccine delivery methods. Vaccines 2013, 1200-1231. Elsevier/Saunders, Philadelphia. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
18. Stingl G., Steiner G. Immunological host defense of the skin. Curr Probl Dermatol 1989, 18:22-30.
19. Steinhoff M., Brzoska T., Luger T.A. Keratinocytes in epidermal immune responses. Curr Opin Allergy Clin Immunol 2001, 1:469-476.
20. Karande P., Mitragotri S. Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies. Ann Rev Chem Biomol Eng 2010, 1:175-201.
21. Glenn G.M., Kenney R.T. Mass vaccination: solutions in the skin. Curr Top Microbiol Immunol 2006, 304:247-268.
22. Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot Int 2004, 19:95-103.
23. Levine M.M. Can needle-free administration of vaccines become the norm in global immunization?. Nat Med 2003, 9:99-103.
24. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005, 5:905-916.
25. Kim Y.C., Quan F.S., Yoo D.G., Compans R.W., Kang S.M., Prausnitz M.R. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 2010, 201:190-198.
26. Fernando G.J., Chen X., Prow T.W., Crichton M.L., Fairmaid E.J., Roberts M.S., et al. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS ONE 2010, 5:e10266.
27. Kim Y.C., Quan F.S., Compans R.W., Kang S.M., Prausnitz M.R. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Rel 2010, 142:187-195.
28. Jaimes M.C., Rojas O.L., Gonzalez A.M., Cajiao I., Charpilienne A., Pothier P., et al. Frequencies of virus-specific CD4(+) and CD8(+) T lymphocytes secreting gamma interferon after acute natural rotavirus infection in children and adults. J Virol 2002, 76:4741-4749.
29. Moon S., Wang Y., Dennehy P., Simonsen K.A., Zhang J., Jiang B. Antigenemia, RNAemia, and innate immunity in children with acute rotavirus diarrhea. FEMS Immunol Med Microbiol 2012, 64:382-391.
30. Jiang B., Estes M.K., Barone C., Barniak V., O'Neal C.M., Ottaiano A., et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 1999, 17:1005-1013.
31. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002, 109:1519-1526.
32. Shortman K., Liu Y.J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002, 2:151-161.
33. Kupper T.S., Fuhlbrigge R.C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev 2004, 4:211-222.
34. De Becker G., Sornasse T., Nabavi N., Bazin H., Tielemans F., Urbain J., et al. Immunoglobulin isotype regulation by antigen-presenting cells in vivo. Eur J Immunol 1994, 24:1523-1528.
35. Hancock G.E., Speelman D.J., Frenchick P.J., Mineo-Kuhn M.M., Baggs R.B., Hahn D.J. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine 1995, 13:391-400.